Cargando…
Direct Ras G12C inhibitors: crossing the rubicon
Despite its status as the most commonly mutated oncogene in cancer, Ras has long been considered ‘undruggable’. In 2019, we will see the first clinical trial results for direct mutant Ras inhibitors, a result of persistent cross-disciplinary research that has been informed by a number of previous cl...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2019
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738074/ https://www.ncbi.nlm.nih.gov/pubmed/31239544 http://dx.doi.org/10.1038/s41416-019-0499-1 |